FDA warned outsourcing facility ASP Cares about sterile compounded drugs made under insanitary conditions and with CGMP violations.
What happened
FDA inspected ASP Cares' San Antonio, Texas facility from August 14 to August 23, 2018. The investigator found sterile drug products prepared under conditions that may have allowed contamination, plus CGMP violations, and said the firm's adverse event reporting procedures were inadequate. FDA also said the firm's compounded drugs lacked FDA-approved applications and adequate directions for use.
What FDA found
FDA found sterile drug products prepared under insanitary conditions, including inadequate smoke studies and pressure monitoring and a crack in cleanroom caulking.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm failed to establish and follow written procedures to prevent microbiological contamination of sterile drugs, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)The firm failed to thoroughly investigate unexplained discrepancies or batch failures, whether or not the batch had been distributed.
21 CFR 211.192The firm failed to test each batch for identity and strength of active ingredients before release.
21 CFR 211.165(a)The firm's adverse event reporting procedure did not adequately define serious or unexpected adverse events.
FDCA section 503B(b)(5) [21 U.S.C. § 353b(b)(5)]; 21 CFR 211.198The firm's compounded drugs lacked FDA-approved applications and adequate directions for use.
FDCA sections 505(a), 301(d), 502(f)(1) [21 U.S.C. §§ 355(a), 331(d), 352(f)(1)]
What FDA wants
FDA asks the firm to notify the compliance office in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documents. If the firm cannot fully address the matter in that time, it must state the reason and the time needed.
Who should pay attention
- hospitals and clinics that buy compounded sterile drugs
- pharmacies and prescribers that use ASP Cares products
- other outsourcing facilities with sterile compounding operations
This is a summary. Read the original letter on fda.gov.